جهت دسترسی به کاربرگه ی زیر، از این لینک استفاده کنید.
|Title:||2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement|
|Authors:||Reardon, Michael J.;Adams, David H.;Kleiman, Neal S.;Yakubov, Steven J.;Coselli, Joseph S.;Deeb, G. Michael;Gleason, Thomas G.;Lee, Joon Sup;Hermiller, James B.;Chetcuti, Stan;Heiser, John;Merhi, William;Zorn, George L.;Tadros, Peter;Robinson, Newell;Petr|
|Abstract:||Background The U.S. pivotal trial for the self-expanding valve found that among patients with severe aortic stenosis at increased risk for surgery, the 1-year survival rate was 4.9 percentage points higher in patients treated with a self-expanding transcatheter aortic valve bioprosthesis than in those treated with a surgical bioprosthesis. Objectives Longer-term clinical outcomes were examined to confirm if this mortality benefit is sustained. Methods Patients with severe aortic stenosis who were at increased surgical risk were recruited. Eligible patients were randomly assigned in a 1:1 ratio to transcatheter aortic valve replacement with the self-expanding transcatheter valve (transcatheter aortic valve replacement [TAVR] group) or to aortic valve replacement with a surgical bioprosthesis (surgical group). The 2-year clinical and echocardiographic outcomes were evaluated in these patients. Results A total of 797 patients underwent randomization at 45 centers in the United States. The rate of 2-year all-cause mortality was significantly lower in the TAVR group (22.2%) than in the surgical group (28.6%; log-rank test p < 0.05) in the as-treated cohort, with an absolute reduction in risk of 6.5 percentage points. Similar results were found in the intention-to-treat cohort (log-rank test p < 0.05). The rate of 2-year death or major stroke was significantly lower in the TAVR group (24.2%) than in the surgical group (32.5%; log-rank test p = 0.01). Conclusions In patients with severe aortic stenosis who are at increased surgical risk, the higher rate of survival with a self-expanding TAVR compared with surgery was sustained at 2 years. (Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement; NCT01240902).|
|More Information:||VOLUME : 66 ISSUE : 2 START PAGE : 113 END PAGES : 121|
|Appears in Collections:||Journal of the American College of Cardiology|
Files in This Item:
|2018 JACC Volume 72 Issue 22 December (3).pdf||675.22 kB||Adobe PDF|
Download Request a copy
تمامی کاربرگه ها در کتابخانه ی دیجیتال حنان به صورت کامل محافظت می شوند.